Melissa Rikal, MSN, FNP-BC, AOCNP®, of SCRI Oncology Partners, talks about an update from the phase Ib/II ELEVATE study, which is examining the oral selective estrogen degrader (SERD) elacestrant in combination with capivasertib in patients with estrogen receptor–positive, HER2-negative advanced breast cancer. At the 2026 ASCO Annual Meeting, an analysis was presented of the updated phase Ib safety and preliminary efficacy for elacestrant plus capivasertib in this patient population (Abstract 1098). 

Melissa Rikal, MSN, FNP-BC, AOCNP®, of SCRI Oncology Partners, discusses progression free survival-2 data from the SERENA-6 trial. Per the investigators, “These results continue to support a switch to [camizestrant in combination with a CDK4/6 inhibitor] for patients with [an] ESR1 [mutation] during first-line therapy to delay disease progression and deteriorations in quality of life.” For advanced practitioners, the potential future approval of camizestrant may mean incorporating more frequent liquid biopsy testing during first-line therapy for these emergent genetic mutations (Abstract LBA1007). 

Melissa Rikal, MSN, FNP-BC, AOCNP®, of SCRI Oncology Partners, presents findings from the phase III VIKTORIA-1 Study 2. The randomized, open-label trial evaluated, in two cohorts by PIK3CA status, gedatolisib-based regimens in HR-positive/HER2-negative advanced breast cancer that progressed during/after therapy with a CDK4/6 inhibitor plus aromatase inhibitor. The data presented at the 2026 ASCO Annual Meeting were the primary findings from the PIK3CA-mutant cohort. She touches on some special considerations for advanced practitioners who may use gedatolisib, including the role of next-generation sequencing and the drug’s unique administration needs (Abstract LBA1008).